EUCTR2018-000821-29-DE进行中（未招募）1 期
A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized,Double-blind, Parallel-group, Placebo-controlled, Active-comparator,Dose-optimization Evaluation followed by a 1-Year Open-label Evaluationto Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 to 17 Years withAttention-deficit/Hyperactivity Disorder
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 288
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is a male or female aged 6 to 17 years inclusive at the time of consent/assent.
- •2. Subject must meet DSM-5 criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation using the Kiddie-Schedule for Affective Disorders-Present and Lifetime Version (K-SADSPL) by a trained child and adolescent psychiatrist at screening (Visit 1A).
- •3. Subject for whom prior stimulant therapy is not suitable, not tolerated, or shown to be ineffective as determined by investigator clinical assessment and review of the Prior Stimulant Medication Questionnaire (PSMQ) administered during screening (Visit 1A).
- •4. Subject has an ADHD-RS-5 total score =28 at baseline (Visit 2A).
- •5. Subject has a baseline (Visit 2A) CGI-S score =4.
- •6. Subject who is a female of childbearing potential (FOCP) and postmenarchal must have a negative serum beta-human chorionic gonadotropin (ß-hCG) pregnancy test at screening (Visit 1A) and a negative urine pregnancy test at baseline (Visit 2A), be nonlactating, and agree to comply with any applicable contraceptive requirements described in the protocol. Female of childbearing potential is defined as any female subject who is at least aged 9 years or younger than 9 years and postmenarchal.
- •7. Subject’s parent or legally authorized representative (LAR) must provide signature of informed consent. Documentation of assent (if applicable) must be provided by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions in accordance with the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related procedures.
- •8. Subject and parent/LAR are willing and able to comply with all the testing and requirements defined in this protocol, including oversight of morning dosing. Specifically, the parent/LAR must be available for the duration of the study to administer the IMP dose each morning when the subject awakens.
- •9. Subject has supine and standing blood pressure (BP) measurements less than the 95th percentile for age, sex, and height at both screening (Visit 1A) and baseline (Visit 2A).
- •10. Subject is functioning at an age-appropriate level intellectually, as judged by the investigator.
- •11. Subject is able to swallow intact tablets and capsules.
- •1.Female subjects of child-bearing potential must have a negative serum ß-hCG pregnancy test at baseline and agree to comply with any applicable contraceptive requirements of the protocol. An FOCP is defined as any female subject who is at least aged 9 years or younger than 9 years and postmenarchal.
- •2.Subject has a supine and standing BP measurement less than the 95th percentile for age, sex, and height.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 288
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subject has a current, controlled (requiring medication or therapy) or uncontrolled, comorbid psychiatric disorder (except oppositional defiant disorder), including but not limited to any of the following comorbid Axis I and Axis II disorders (the K-SADS-PL should be reviewed to confirm diagnosis, if necessary):
- •a.Post-traumatic stress disorder (PTSD)
- •b.Bipolar illness, psychosis, or family history in either biological parent
- •c.Pervasive developmental disorder
- •d.Obsessive-compulsive disorder (OCD)
- •e.Psychosis/schizophrenia
- •f.Serious tic disorder or a family history of Tourette’s disorder
- •2.Subject is currently considered to be a suicide risk by the investigator; has made a previous suicide attempt; has a history of, or currently demonstrating, active suicidal ideation.
- •3.Subject has a substance abuse disorder as defined by DSM-5 criteria or has been suspected of a substance abuse or dependence disorder (except nicotine) within the past 6 months.
- •4.Subject has a clinically important abnormality on the urine drug and alcohol screen (except for the subject’s current ADHD stimulant, if applicable) at screening (Visit 1A).
- •5.Subject has been physically, sexually, and/or emotionally abused.
- •6.Subject has any other disorder that as judged by the investigator could contraindicate TAK503 or confound the results of the safety and efficacy assessments.
- •7.Subject has any condition or illness including any clinically significant abnormal laboratory value at screening (Visit 1A) or, if the laboratory test was repeated, at baseline (Visit 2A) that, as judged by the investigator, would be an inappropriate risk to the subject and/or could confound the interpretation of study results.
- •8.Subject has current abnormal thyroid function, defined as abnormal thyroid-stimulating hormone and thyroxine at screening (Visit 1A). Treatment with a stable dose of thyroid medication for =3 months before screening will be permitted.
- •9.Subject has a known history or presence of: malignancy (except nonmelanoma skin cancer), pregnancy, and/or a developmental delay or abnormality associated with growth or sexual maturation delays that are not related to ADHD.
- •10.Children aged 6 to 12 years with a body weight <25.0 kg or adolescents aged =13 years with a body weight <34.0 kg at screening (Visit 1A) or baseline (Visit 2A).
- •11.Subject is significantly overweight based on the Centers for Disease Control (CDC) BMI-for-age sex-specific charts at screening (Visit 1A) or baseline (Visit 2A). For this study, significantly overweight will be defined as a BMI that is greater than the 95th percentile.
- •12.Subject has a known history or presence of: structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems (eg, clinically significant heart block or QT interval prolongation), bradycardia, or exercise-related cardiac events including syncope and presyncope.
- •13.Subject has clinically significant ECG findings, as judged by the investigator, at baseline (Visit 2A).
- •14.Subject has orthostatic hypotension* or a known history of hypertension.
- •(*Orthostatic hypotension is defined as a sustained reduction of systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of 10 mm Hg within 3 minutes of standing from supine.)
- •15.Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
- •16.Subject is currently using any medication that violates protocol-specified washout criteria at baseline (Visit 2A), i
研究者
相似试验
进行中（未招募）
1 期
A Phase 4 study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 to 17 Years with ADHDAttention-deficit/hyperactivity disorder (ADHD)MedDRA version: 21.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2018-000821-29-ESShire Development LLC288
进行中（未招募）
1 期
A Phase 4 study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 to 17 Years with ADHDEUCTR2018-000821-29-BETakeda Development Center Americas, Inc.288
招募中
4 期
A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-Deficit/Hyperactivity DisorderAttention-deficit/hyperactivity disorder (ADHD)NL-OMON55836Takeda20
进行中（未招募）
1 期
A Phase 4 study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 to 17 Years with ADHDEUCTR2018-000821-29-SETakeda Development Center Americas, Inc.288
进行中（未招募）
1 期
A Phase 4 study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 to 17 Years with ADHDAttention-deficit/hyperactivity disorder (ADHD)MedDRA version: 21.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2018-000821-29-GBShire Development LLC288